RxDoctor Payments Data

Shawn Churchill Coy

Psychiatric/Mental Health · Columbus, MSNPI 1255425922

Payments from drug & device makers

$668in general payments, 2019–2025

Across 28 payments — averaging $23.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$137
  • Bayer$120
  • AbbVie$117
  • Otsuka America Pharmaceutical, Inc.$114
  • Neurocrine Biosciences, Inc.$94
  • Johnson & Johnson$45
  • plus $42 from 2 others

What the payments were for

  • Food & beverage$668100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$668 in reported general payments places this provider in the 45th percentile of 486 psychiatric/mental health providers in Mississippi.

See all psychiatric/mental health providers in Mississippi

Medicare billing

Part B allowed, 2024
$8,466
Medicare patients
52
Services billed
87

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole33$51,984
VraylarCariprazine Hcl27$36,425
Abilify MaintenaAripiprazole11$30,498
Lurasidone Hcl42$13,959
TrintellixVortioxetine Hydrobromide12$5,541
Chlorpromazine Hcl18$2,232
Buspirone Hcl141$2,075
Vilazodone Hcl20$1,944
Ziprasidone Hcl38$1,580
Aripiprazole42$1,375
Trazodone Hcl115$1,222
Quetiapine Fumarate77$1,032
Bupropion XlBupropion Hcl58$993
Haloperidol Decanoate24$971
Divalproex Sodium ErDivalproex Sodium39$968

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$114$82,48244 claims
AbbVieVraylar$117$36,42527 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 486 psychiatric/mental health providers in Mississippi.

Other psychiatric/mental health in Columbus

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →